Literature DB >> 12706521

ECT response in delusional versus non-delusional depressed inpatients.

Tom K Birkenhäger1, Esther M Pluijms, Stefan A P Lucius.   

Abstract

BACKGROUND: ECT is often considered more effective in delusional than in non-delusional depressives, although the literature does not support this view.
METHODS: We reviewed the records of 55 consecutive inpatients with major depression according to the DSM-III-R criteria and distinguished two subtypes: patients with delusions and those without. We examined whether the deluded patients showed a higher response rate.
RESULTS: using 50% reduction on the Hamilton Rating Scale for Depression (HRSD) as response criterion, the efficacy of ECT was higher in patients with delusional depression (92% response) than in the non-deluded patients (55% response). Considering a post-ECT HRSD score of < or =7 as response criterion, patients with delusions again showed a higher response rate (57% versus 24%). LIMITATIONS: this study has a retrospective nature and a rather homogeneous sample.
CONCLUSION: ECT appears to be an effective treatment for severely depressed inpatients, both with and without delusions. The efficacy of ECT was superior in patients with delusional depression, considering the number of patients achieving partial remission as well as full remission.

Entities:  

Mesh:

Year:  2003        PMID: 12706521     DOI: 10.1016/s0165-0327(02)00005-8

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  11 in total

1.  Persistent delusional theme over 13 episodes of psychotic depression.

Authors:  S D Ostergaard; A K Leadholm; A J Rothschild
Journal:  Acta Neuropsychiatr       Date:  2013-12       Impact factor: 3.403

2.  Relief of expressed suicidal intent by ECT: a consortium for research in ECT study.

Authors:  Charles H Kellner; Max Fink; Rebecca Knapp; Georgios Petrides; Mustafa Husain; Teresa Rummans; Martina Mueller; Hilary Bernstein; Keith Rasmussen; Kevin O'connor; Glenn Smith; A John Rush; Melanie Biggs; Shawn McClintock; Samuel Bailine; Chitra Malur
Journal:  Am J Psychiatry       Date:  2005-05       Impact factor: 18.112

Review 3.  Psychotic depression--beyond the antidepressant/antipsychotic combination.

Authors:  Erik B Nelson
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

4.  Measuring psychotic depression.

Authors:  S D Østergaard; B S Meyers; A J Flint; B H Mulsant; E M Whyte; C M Ulbricht; P Bech; A J Rothschild
Journal:  Acta Psychiatr Scand       Date:  2013-06-25       Impact factor: 6.392

Review 5.  Rating scales measuring the severity of psychotic depression.

Authors:  S D Østergaard; A J Rothschild; A J Flint; B H Mulsant; E M Whyte; A K Leadholm; P Bech; B S Meyers
Journal:  Acta Psychiatr Scand       Date:  2015-05-27       Impact factor: 6.392

6.  Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account.

Authors:  Søren D Østergaard; Barnett S Meyers; Alastair J Flint; Benoit H Mulsant; Ellen M Whyte; Christine M Ulbricht; Per Bech; Anthony J Rothschild
Journal:  J Affect Disord       Date:  2014-01-02       Impact factor: 4.839

Review 7.  Co-occurring depressive symptoms in the older patient with schizophrenia.

Authors:  John W Kasckow; Sidney Zisook
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 8.  Challenges in the treatment of major depressive disorder with psychotic features.

Authors:  Anthony J Rothschild
Journal:  Schizophr Bull       Date:  2013-04-18       Impact factor: 9.306

Review 9.  Time course of response to antidepressants in late-life major depression: therapeutic implications.

Authors:  Ellen M Whyte; Mary Amanda Dew; Ariel Gildengers; Eric J Lenze; Ashok Bharucha; Benoit H Mulsant; Charles F Reynolds
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 10.  Clinical and molecular genetics of psychotic depression.

Authors:  Katharina Domschke
Journal:  Schizophr Bull       Date:  2013-03-19       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.